|

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

RECRUITINGSponsored by Eisai Korea Inc.
Actively Recruiting
SponsorEisai Korea Inc.
Started2025-02-24
Est. completion2029-09-30
Eligibility
Age19 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06810960

Summary

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
* The clinical decision to treat with LEQEMBI has already been made
* Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

Exclusion Criteria:

* Currently participating in an interventional clinical study

Conditions1

Alzheimer's Disease

Locations1 site

Eisai Trial Site #1
Nutley, New Jersey, 07110

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.